Anika Therapeutics
ANIK
163 hedge funds and large institutions have $532M invested in Anika Therapeutics in 2016 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 58 reducing their positions, and 15 closing their positions.
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
2% more funds holding
Funds holding: 160 → 163 (+3)
5% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 58
14% less capital invested
Capital invested by funds: $617M → $532M (-$85.1M)
41% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $1.8M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.32M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.61M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$3.94M |
| 4 |
Goldman Sachs
New York
|
+$2.85M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$10.3M |
| 2 |
GAM
Gotham Asset Management
New York
|
-$5.88M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$4.52M |
| 4 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$4.24M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$4.07M |
ANIK Hedge Fund Activity: Q3 2016 in Review
163 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2016, worth a combined $532M — down 14% from $617M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ANIK positions and 15 closed out — a net gain of 3 holders — while 61 added to existing stakes and 58 trimmed.
The largest buyer was Millennium Management, adding an estimated $7.32M. The largest seller was HealthInvest Partners, cutting an estimated $10.3M.
- 163 institutional investors held Anika Therapeutics (ANIK) as of Q3 2016, up from 160 in Q2 2016.
- Funds reported $532M of Anika Therapeutics stock for Q3 2016, down 14% quarter-over-quarter.
- 18 funds opened new Anika Therapeutics positions in Q3 2016 and 15 closed out, a net change of +3 holders.
- The largest Anika Therapeutics buyer in Q3 2016 was Millennium Management, an estimated $7.32M added.
- The largest Anika Therapeutics seller in Q3 2016 was HealthInvest Partners, an estimated $10.3M sold.
Based on aggregated 13F filings for Q3 2016.